Evaluation of plasma PDGF and VEGF levels after systemic administration of activated autologous platelet-rich plasma
Keywords:Activated autologous platelet-rich plasma (aaPRP), platelet derived growth factor (PDGF), vascular endothelial growth factor (VEGF)
Introduction and Aim: Activated autologous platelet-rich plasma (aaPRP) is becoming a popular therapy to accelerate healing in the field of plastic surgery. Platelets, which are abundant in aaPRP, can release many growth factors including platelet-derived growth factor (PDGF) and vascular endothelial growth factor (VEGF). This study aims to examine the plasma levels of PDGF and VEGF in healthy subjects after intravenous administration of aaPRP.
Materials and Methods: Nine healthy patients with no prior history of metabolic disease were divided into two groups (control and experiment group). The treatment group which consists of six patients received intravenous aaPRP treatment. The preparation of aaPRP starts with the collection of 24 mL of whole blood in sodium citrate tubes followed a two-step centrifugation procedure and subsequent chemical activation. aaPRP was then administered intravenously to patients. Meanwhile, the control group received no intervention. Venous blood samples were taken before and one week after the treatment and the plasma PDGF and VEGF levels were determined by enzyme-linked immunosorbent assay (ELISA).
Results: The treatment group showed statistically significant increase in VEGF after 7 days compared to before aaPRP administration. However, the change in PDGF levels of the treatment group was unnotable.
Conclusion: The present findings indicate that intravenous administrations of activated aaPRP may increase plasma VEGF level up to 1 week after aaPRP administration.
Marx,R.E. Platelet-rich plasma: evidence to support its use. J Oral Maxillofac Surg. 2004;62(4):489-496.
Pavlovic, V., Ciric, M., Jovanovic, V., Stojanovic, P. Platelet rich plasma: a short overview of certain bioactive components. Open Med. 2016;11(1):242-247.
Cole, B.J., Seroyer, S.T., Filardo, G., Bajaj, S., Fortier, L.A. Platelet-rich plasma: Where are we now and where are we going? Sports Health. 2010;2(3):203-210.
Suryani, D., Pawitan, J.A., Lilianty, J., Purwoko, R.Y., Liem, I.K., Damayanti, L. Comparison of fetal bovine serum and platelet-rich plasma on human lipoaspirate-derived mesenchymal stem cell proliferation. Med J Indones. 2013;22(3):146-151.
Karina, K., Samudra, M.F., Rosadi, I., Afini, I., Widyastuti, T., Sobariah, S., et al., Combination of the stromal vascular fraction and platelet-rich plasma accelerates the wound healing process: Pre-clinical study in a Sprague-Dawley rat model. Stem Cell Investig. 2019;6(18).
Chakravdhanula, U., Anbarasu, K., Verma, V.K., Beevi, S.S. Clinical efficacy of platelet rich plasma in combination with methotrexate in chronic plaque psoriatic patients. Dermatol Ther. 2016;29(6):446-450.
Freitag, J. The effect of photoactivated platelet-rich plasma injections in the novel treatment of shoulder osteoarthritis. Int J Case Reports Images. 2014;5(8):546-552.
Hurley, E.T., Fat, D.L., Moran, C.J., Mullett, H. The efficacy of platelet-rich plasma and platelet-rich fibrin in arthroscopic rotator cuff repair: a meta-analysis of randomized controlled trials. Am J Sports Med. 2019;47(3):753-761.
Rosadi, I., Karina, K., Rosliana, I., Sobariah, S., Afini, I., Widyastuti, T., et al.,The effect of human platelet-rich plasma and L-ascorbic acid on morphology, proliferation, and chondrogenesis ability towards human adipose-derived stem cells. Mol Cell Biomed Sci. 2019;3(1):26-33.
Karina, K., Rosliana, I., Rosadi, I., Schwartz, R., Sobariah, S., Afini, I., et al., Safety of technique and procedure of stromal vascular fraction therapy: from liposuction to cell administration. Scientifica (Cairo). 2020;1-11.
Masuki, H., Okudera, T., Watanebe, T., Suzuki, M., Nishiyama, K.,Okudera, H., et al., Growth factor and pro-inflammatory cytokine contents in platelet-rich plasma (PRP), plasma rich in growth factors (PRGF), advanced platelet-rich fibrin (A-PRF), and concentrated growth factors (CGF). Int J Implant Dent. 2016;2(1):19.
Chen, J., Jiang, H. A comprehensive review of concentrated growth factors and their novel applications in facial reconstructive and regenerative medicine. Aesthetic Plast Surg. 2020;44(3):1047-1057.
Yamakawa, S., Hayashida, K. Advances in surgical applications of growth factors for wound healing. Burn Trauma. 2019;5(7):10.
Karina, K., Wahyuningsih, K.A., Sobariah, S., Rosliana, I., Rosadi, I., Widyastuti, T., et al.,Evaluation of platelet-rich plasma from diabetic donors shows increased platelet vascular endothelial growth factor release. Stem Cell Investig. 2019;20(6):43.
Irmak, G., Demirta?, T.T., Gümü?derelio?lu, M. Sustained release of growth factors from photoactivated platelet rich plasma (PRP). Eur J Pharm Biopharm. 2020;148:67-76.
Paterson, K.L., Nicholls, M., Bennell, K.L., Bates, D. Intra-articular injection of photo-activated platelet-rich plasma in patients with knee osteoarthritis: A double-blind, randomized controlled pilot study. BMC Musculoskelet Disord. 2016;9(17):67.
Cavallo, C., Roffi, A., Grigolo, B., Mariani, E., Pratelli, L., Merli, G., et al., Platelet-Rach Plasma: The Choice of activation method affects the release of bioactive molecules. Biomed Res Int. 2016;1:1-7.
Gianni-Barrera, R., Burger, M., Wolff, T., Heberer, M., Schaefer, D.J., Gürke, L., et al., Long-term safety and stability of angiogenesis induced by balanced single-vector co-expression of PDGF-BB and VEGF164 in skeletal muscle. Sci Rep. 2016;6(1):21546.
Shi, S., Mercer, S., Eckert, G.J., Trippel, S.B. Growth factor regulation of growth factors in articular chondrocytes. J Biol Chem. 2009;284(11):6697-6704.
Müller-Deile, J., Worthmann, K., Saleem, M., Tossidou, I., Haller, H., Schiffer, M. The balance of autocrine VEGF-A and VEGF-C determines podocyte survival. Am J Physiol - Ren Physiol. 2009;297(6):1656-1667.
Onions, K.L., Gamez, M., Buckner, N.R., Baker, S.L., Betteridge, K.B., Desideri, S., et al.,VEGFC reduces glomerular albumin permeability and protects against alterations in VEGF receptor expression in diabetic nephropathy. Diabetes. 2019;68(1):172-187.
How to Cite
This work is licensed under a Creative Commons Attribution 4.0 International License.